Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.42 +0.4%	$0.39	$0.30 ▼ $10.62	$59.60M	1.82	3.47 million shs	3.64 million shs
AVTX Avalo Therapeutics	$4.80 -2.0%	$4.43	$3.39 ▼ $16.00	$53.06M	0.77	64,334 shs	32,067 shs
IPSC Century Therapeutics	$0.58 -3.6%	$0.57	$0.34 ▼ $3.29	$51.69M	1.78	572,711 shs	1.01 million shs
MTVA MetaVia	$0.67 -6.0%	$0.70	$0.60 ▼ $5.04	$13.91M	0.21	67,581 shs	44,711 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	+0.40%	+14.55%	+19.41%	+39.14%	-92.88%
AVTX Avalo Therapeutics	-2.04%	-1.03%	-0.83%	+3.67%	-60.82%
IPSC Century Therapeutics	-3.58%	+2.83%	+0.52%	+15.68%	-78.97%
MTVA MetaVia	-5.97%	+4.53%	-8.82%	-9.10%	+66,749,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.5036 of 5 stars	3.3	3.0	4.7	3.3	1.7	1.3
AVTX Avalo Therapeutics	3.1524 of 5 stars	3.5	3.0	0.0	2.7	1.7	1.3
IPSC Century Therapeutics	3.2812 of 5 stars	3.5	5.0	0.0	2.4	1.7	0.6
MTVA MetaVia	1.7351 of 5 stars	3.5	0.0	0.0	1.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,343.10% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	525.00% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	626.14% Upside
MTVA MetaVia	3.00	Buy	$7.50	1,023.60% Upside

Current Analyst Ratings Breakdown

Latest MTVA, APLT, IPSC, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
4/16/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	130.10	N/A	N/A	$0.49 per share	0.86
AVTX Avalo Therapeutics	$440K	118.15	N/A	N/A	$12.80 per share	0.38
IPSC Century Therapeutics	$6.59M	7.56	N/A	N/A	$1.90 per share	0.30
MTVA MetaVia	N/A	N/A	N/A	N/A	$0.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
MTVA MetaVia	-$27.59M	N/A	0.00	N/A	N/A	N/A	-222.13%	-123.85%	8/13/2025 (Estimated)

Latest MTVA, APLT, IPSC, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	MTVA MetaVia	-$0.32	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/14/2025	Q1 2025	MTVA MetaVia	-$0.57	-$0.36	+$0.21	-$0.36	N/A	N/A
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	3.00	3.00
AVTX Avalo Therapeutics	N/A	22.61	22.61
IPSC Century Therapeutics	N/A	11.70	11.70
MTVA MetaVia	N/A	1.55	1.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
AVTX Avalo Therapeutics	87.06%
IPSC Century Therapeutics	50.20%
MTVA MetaVia	1.37%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
AVTX Avalo Therapeutics	0.25%
IPSC Century Therapeutics	5.00%
MTVA MetaVia	0.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.80 million	Not Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
MTVA MetaVia	8	19.59 million	19.43 million	N/A

MTVA, APLT, IPSC, and AVTX Headlines

Recent News About These Companies

MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...

July 10, 2025 | finanznachrichten.de

MetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trial

July 10, 2025 | msn.com

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

July 9, 2025 | prnewswire.com

OTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCR

June 27, 2025 | msn.com

MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…

June 24, 2025 | finance.yahoo.com

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

June 21, 2025 | prnewswire.com

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

June 10, 2025 | financialpost.comF

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

June 10, 2025 | globenewswire.com

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

June 4, 2025 | prnewswire.com

MTVA stock touches 52-week low at $0.64 amid market challenges

June 1, 2025 | uk.investing.com

MetaVia Faces Nasdaq Delisting Notice for Low Stock Price

May 30, 2025 | tipranks.com

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…

May 22, 2025 | finance.yahoo.com

MetaVia Updates Corporate Presentation on DA-1726 Progress

May 21, 2025 | tipranks.com

MetaVia Inc.: MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025 | finanznachrichten.de

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 9, 2025 | prnewswire.com

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

May 7, 2025 | prnewswire.com

MetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 study

April 24, 2025 | markets.businessinsider.com

MetaVia Advances Pipeline Targeting Obesity, Diabetes, and MASH; Phase 2a Data on DA-1241 to be Presented at EASL 2025

April 23, 2025 | theglobeandmail.com

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

April 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, APLT, IPSC, and AVTX Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.42 +0.00 (+0.40%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.42 0.00 (-0.64%)

As of 07/15/2025 07:59 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Avalo Therapeutics NASDAQ:AVTX

$4.80 -0.10 (-2.04%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$4.84 +0.04 (+0.94%)

As of 07/15/2025 05:03 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Century Therapeutics NASDAQ:IPSC

$0.58 -0.02 (-3.58%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.61 +0.03 (+5.12%)

As of 07/15/2025 07:37 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

MetaVia NASDAQ:MTVA

$0.67 -0.04 (-5.97%)

As of 07/15/2025 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time